Cancer Research The Future of Cancer Research: Science and Patient Impact
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 28, 564-570, March 1, 1968]
© 1968 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kessel, D.
Right arrow Articles by Roberts, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kessel, D.
Right arrow Articles by Roberts, D.

Modes of Uptake of Methotrexate by Normal and Leukemic Human Leukocytes in Vitro and Their Relation to Drug Response1

David Kessel, Thomas C. Hall and DeWayne Roberts

Laboratories of Pharmacology, The Children's Cancer Research Foundation, and the Departments of Pathology and Medicine, Harvard Medical School, Boston, Massachusetts 02115

Characteristics of Methotrexate transport by normal and leukemic human leukocytes were measured in vitro. At high external drug levels (greater double equals20 µM) drug uptake by all cell types was temperature-insensitive, nonsaturable, and nonconcentrative. The steady-state cell/medium drug distribution ratio was about 0.03. During clinical treatment with Methotrexate, plasma drug levels generally reach 0.2 µM. At this lower drug level: (a) A temperature-sensitive and saturable mode of transport was demonstrable in all cell types except small lymphocytes. In normal granulocytes the steady-state drug distribution ratio reached 0.2. (b) Leukemic cell types showed a wide variation in capacity for uptake of the drug, and an association was seen between this capacity and clinical response to the drug.

1 Supported by Contracts PH 43-62-169 and PH 43-66-541 of the Cancer Chemotherapy National Service Center, and by Grant C 6516, all from the National Cancer Institute, NIH.

Received 6/28/67. Accepted 11/23/67.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1968 by the American Association for Cancer Research.